Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S

Biochemical and Biophysical Research Communications

Volumn 389, Issue 2, 2009, Pages 295-300

  Bihani, Subhash C ^a   Das, Amit ^a   Prashar, Vishal ^a   Ferrer, J L ^b   Hosur, M V ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b INSTITUT DE BIOLOGIE STRUCTURALE   (France)

Author keywords

Drug resistance; HIV 1 protease; Mutation; X ray crystallography

Indexed keywords

NELFINAVIR; PROTEINASE;

ARTICLE; CRYSTAL STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL;

ASPARAGINE; ASPARTIC ACID; CARBAMATES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; HYDROGEN BONDING; MUTATION; NELFINAVIR; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70349335348     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.08.138     Document Type: Article

References (42)

1. M.C. Heagarty, AIDS: the Battle Rages On, Issues in science and technology online, Summer 2003. Available from: .
2. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A., Scolnick E.M., and Sigal I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85 (1988) 4686-4690
3. Wlodawer A., and Vondrasek J. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. Annu. Rev. Biophys. Biomol. Struct. 27 (1998) 249-284
4. Wolfenden R. Conformational aspects of inhibitor design: enzyme-substrate interactions in the transition state. Bioorg. Med. Chem. 7 (1999) 647-652
5. Hertogs K., Bloor S., Kemp S.D., Van den Eynde C., Alcorn T.M., Pauwels R., Van Houtte M., Staszewski S., Miller V., and Larder B.A. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14 (2000) 1203-1210
6. Martinez-Cajas J.L., and Wainberg M.A. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antivir. Res. 76 (2007) 203-221
7. Ridky T., and Leis J. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270 (1995) 29621-29623
8. Wu T.D., Schiffer C.A., Gonzales M.J., Taylor J., Kantor R., Chou S., Israelski D., Zolopa A.R., Fessel W.J., and Shafer R.W. Mutation pattern and structural correlates in human immunodeficiency virus type-1 protease following different protease inhibitor treatments. J. Virol. 77 (2003) 4836-4847
9. Xie D., Gulnik S., Gustchina E., Yu B., Shao W., Qoronfleh W., Nathan A., and Erickson J.W. Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH. Protein Sci. 8 (1999) 1702-1707
10. Piana S., Carloni P., and Rothlisberger U. Drug resistance in HIV-1 protease: flexibility-assisted mechanism of compensatory mutations. Protein Sci. 11 (2002) 2393-2402
11. Kovalevsky A.Y., Tie Y., Liu F., Boross P.I., Wang Y.-F., Leshchenko S., Ghosh A.K., Harrison R.W., and Weber I.T. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V and L90M. J. Med. Chem. 49 (2006) 1379-1387
12. Kozisek M., Bray J., Rezacova P., Saskova K., Brynda J., Pokorna J., Mammano F., Rulisek L., and Konvalinka J. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants. J. Mol. Biol. 374 (2007) 1005-1016
13. Parera M., Fernandez G., Clotet B., and Martinez M.A. HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions. Mol. Biol. Evol. 24 (2007) 382-387
14. Patick A.K., Duran M., Cao Y., Shugarts D., Keller M.R., Mazabel E., Knowles M., Chapman S., Kuritzkes D.R., and Markowitz M. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42 (1998) 2637-2644
15. Pellegrin I., Breilh D., Montestruc F., Caumont A., Morlat G.P., Camus C.L., Saux M.C., Fleury H.J.A., and Pellegrin J.L. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 16 (2002) 1331-1340
16. Shafer R.W., Stevenson D., and Chan B. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 27 (1999) 348-352
17. Mahalingam B., Louis J.M., Reed C.C., Adomat J.M., Krouse J., Wang Y.F., Harrison F., and Weber I.T. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur. J. Biochem. 263 (1999) 238-245
18. Mitsuya Y., Winters M.A., Fessel W.J., Rhee S.-Y., Hurley L., Horberg M., Schiffer C.A., Zolopa A.R., and Shafer R.W. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res. Hum. Retroviruses 22 (2006) 1300-1305
19. Shafer R.W. Genotypic testing for human immunodeficiency virus type-1 drug resistance. Clin. Microbiol. Rev. 15 (2002) 247-277
20. Gong Y.-F., Robinson B.S., Rose R.E., Deminie C., Spicer T.P., Stock D., Colonno R.J., and Lin P.F. In vitro resistance profile of the human immunodeficiency type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. 44 (2000) 2319-2326
21. Ziermann R., Limoli K., Das K., Arnold E., Petropoulos C.J., and Parkin N.T. A mutation in Human Immunodeficiency Virus type 1 protease, N88S, that caused in vitro hypersensitivity to amprenavir. J. Virol. 74 (2000) 4414-4419
22. Resch W., Ziermann R., Parkin N., Gamarnik A., and Swanstrom R. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the gag polyprotein aberrantly. J. Virol. 76 (2002) 8659-8666
23. Liu F., Kovalevsky A.Y., Louis J.M., Boross P.I., Wang Y.F., Harrison R.W., and Weber I.T. Mechanism of drug resistance revealed by the crystal structure of the unliganded HIV-1 protease with F53L mutation. J. Mol. Biol. 358 (2006) 1191-1199
24. Cheng Y.-S.E., Yin F.H., Foundling S., Blomstrom D., and Kettner C.A. Stability and activity of human immunodeficiency virus protease: comparison of a natural dimer with a homologous single chain tethered dimer. Proc. Natl. Acad. Sci. USA 87 (1990) 9660-9664
25. Kumar M., Kannan K.K., Hosur M.V., Bhavesh N.S., Chatterjee A., Mittal R., and Hosur R.V. Effects of remote mutation on the autolysis of HIV-1 PR: X-ray and NMR investigations. Biochem. Biophys. Res. Commun. 294 (2002) 395-401
26. Pillai B., Kannan K.K., and Hosur M.V. 1.9 Å X-ray study shows closed flap conformation in crystals of tethered HIV-1 protease. Proteins 43 (2001) 57-64
27. Pillai B., Bhat S.V., Kannan K.K., and Hosur M.V. Rapid screening for HIV-1 protease inhibitor leads through X-ray diffraction. Acta Crystallogr. D 60 (2004) 594-596
28. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 26 (1993) 795-800
29. Afonine P.V., Grosse-Kunstleve R.W., and Adams P.D. The Phenix refinement framework. CCP4 Newslett. 42 (2005) (contribution 8)
30. Painter J., and Merritt E.A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D 62 (2006) 439-450
31. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47 (1991) 110-119
32. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60 (2004) 2126-2132
33. Bailey S. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50 (1994) 760-763
34. W.L. DeLano (2002). Available from: .
35. Liang J., Edelsbrunner H., and Woodward C. Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design. Protein Sci. 7 (1998) 1884-1897
36. Hebert E.J., Giletto A., Sevcik J., Urbanikova L., Wilson K.S., Dauter Z., and Pace C.N. Contribution of a conserved asparagine to the conformational stability of ribonucleases Sa, Ba and T1. Biochemistry 37 (1998) 16192-16200
37. Bagossi P., Sperka T., Feher A., Kadas J., Zahuczky G., Miklossy G., Boross P., and Tozser J. Amino acid preferences for a critical substrate binding subsite of retroviral protease in type 1 cleavage sites. J. Virol. 79 (2005) 4213-4218
38. Ishima R., Ghirlando R., Toser J., Gronenborn A.M., and Torchia D.A. Folded monomer of HIV-1 protease. J. Biol. Chem. 276 (2001) 49110-49116
39. Lin Y.C., Beck Z., Morris G.M., Olson A.J., and Elder J.H. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus protease. J. Virol. 77 (2003) 6589-6600
40. Kumar M., and Hosur M.V. Adaptability and flexibility of HIV-1 protease. Eur. J. Biochem. 270 (2003) 1231-1239
41. Zoete V., Michielin O., and Karplus M. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. J. Mol. Biol. 315 (2002) 21-52
42. Prabu-Jeyabalan M., Nalivaika E., and Schiffer C.A. Substrate shape determine specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10 (2002) 369-381